Zacks.com on MSN1h
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
GSK plc GSK announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational ...
GlobalData on MSN2d
Gilead’s Livdelzi shows promise in PBC clinical trial
The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management
Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which ...
The Pharma Letter4d
Gilead’s Livdelzi reduced pruritus severity in PBC participants
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite ...
Business Insider1d
Gilead price target raised to $100 from $85 at Argus
The company ecently announced that the FDA granted accelerated approval for Livdelzi in combination with ursodeoxycholic acidfor the treatment of primary biliary cholangitis, the analyst tells ...
Yahoo Finance2d
Gilead’s Livdelzi shows promise in PBC clinical trial
Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC). The analysis revealed ...
Morningstar5d
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch – Gilead Sciences, Inc. (Nasdaq: GILD)today ...
Nasdaq3d
Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management
Using a data cutoff of January 31, 2024, the interim analysis represented all participants in the ASSURE study, including those who participated in prior clinical studies of Livdelzi (legacy ...
ADVFN4d
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
GILD Gilead Sciences Inc Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis ...